Patents by Inventor Flordeliza Villanueva
Flordeliza Villanueva has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11737971Abstract: The invention pertains to a lipid-based microbubble stably binding a plurality of nucleic acids, and a method of delivering the microbubble and nucleic acids to a specific target site using ultrasound. The delivered nucleic acids create transgenic cells (i.e., for example, a transgenic tumor cell), wherein the transgenic cell expresses the proteins encoded by the delivered nucleic acids. This technology provides a significant improvement for microbubble-drug delivery platforms as known microbubble do not efficiently bind nucleic acids. The improvements described herein include but are not limited to identifying proper lipid proportionality ratios and/or cationic surfactant layers that provide an optimum mechanical index compatible with ultrasonics. Microbubble perfusion and/or nucleic acid delivery may be performed by a combination of imaging and ultrasound/microbubble targeted delivery to simultaneously perform low power two-dimensional imaging and high power microbubble destruction.Type: GrantFiled: March 4, 2020Date of Patent: August 29, 2023Assignee: University Of Pittsburgh—Of The Commonwealth System Of Higher EducationInventors: Flordeliza Villanueva, Andrew Carson, Charles F McTiernan, Jianjun Wang
-
Publication number: 20200214973Abstract: The invention pertains to a lipid-based microbubble stably binding a plurality of nucleic acids, and a method of delivering the microbubble and nucleic acids to a specific target site using ultrasound. The delivered nucleic acids create transgenic cells (i.e., for example, a transgenic tumor cell), wherein the transgenic cell expresses the proteins encoded by the delivered nucleic acids. This technology provides a significant improvement for microbubble-drug delivery platforms as known microbubble do not efficiently bind nucleic acids. The improvements described herein include but are not limited to identifying proper lipid proportionality ratios and/or cationic surfactant layers that provide an optimum mechanical index compatible with ultrasonics. Microbubble perfusion and/or nucleic acid delivery may be performed by a combination of imaging and ultrasound/microbubble targeted delivery to simultaneously perform low power two-dimensional imaging and high power microbubble destruction.Type: ApplicationFiled: March 4, 2020Publication date: July 9, 2020Inventors: Flordeliza Villanueva, Andrew Carson, Charles F. McTiernan, Jianjun Wang
-
Patent number: 10588853Abstract: The invention pertains to a lipid-based microbubble stably binding a plurality of nucleic acids, and a method of delivering the microbubble and nucleic acids to a specific target site using ultrasound. The delivered nucleic acids create transgenic cells (i.e., for example, a transgenic tumor cell), wherein the transgenic cell expresses the proteins encoded by the delivered nucleic acids. This technology provides a significant improvement for microbubble-drug delivery platforms as known microbubble do not efficiently bind nucleic acids. The improvements described herein include but are not limited to identifying proper lipid proportionality ratios and/or cationic surfactant layers that provide an optimum mechanical index compatible with ultrasonics. Microbubble perfusion and/or nucleic acid delivery may be performed by a combination of imaging and ultrasound/microbubble targeted delivery to simultaneously perform low power two-dimensional imaging and high power microbubble destruction.Type: GrantFiled: November 13, 2017Date of Patent: March 17, 2020Assignee: University Of Pittsburgh—Of The Commonwealth System Of Higher EducationInventors: Flordeliza Villanueva, Andrew Carson, Charles F McTiernan, Jianjun Wang
-
Publication number: 20180140542Abstract: The invention pertains to a lipid-based microbubble stably binding a plurality of nucleic acids, and a method of delivering the microbubble and nucleic acids to a specific target site using ultrasound. The delivered nucleic acids create transgenic cells (i.e., for example, a transgenic tumor cell), wherein the transgenic cell expresses the proteins encoded by the delivered nucleic acids. This technology provides a significant improvement for microbubble-drug delivery platforms as known microbubble do not efficiently bind nucleic acids. The improvements described herein include but are not limited to identifying proper lipid proportionality ratios and/or cationic surfactant layers that provide an optimum mechanical index compatible with ultrasonics. Microbubble perfusion and/or nucleic acid delivery may be performed by a combination of imaging and ultrasound/microbubble targeted delivery to simultaneously perform low power two-dimensional imaging and high power microbubble destruction.Type: ApplicationFiled: November 13, 2017Publication date: May 24, 2018Inventors: Flordeliza Villanueva, Andrew Carson, Charles F. McTiernan, Jianjun Wang
-
Patent number: 9844504Abstract: The invention pertains to a lipid-based microbubble stably binding a plurality of nucleic acids, and a method of delivering the microbubble and nucleic acids to a specific target site using ultrasound. The delivered nucleic acids create transgenic cells (i.e., for example, a transgenic tumor cell), wherein the transgenic cell expresses the proteins encoded by the delivered nucleic acids. This technology provides a significant improvement for microbubble-drug delivery platforms as known microbubble do not efficiently bind nucleic acids. The improvements described herein include but are not limited to identifying proper lipid proportionality ratios and/or cationic surfactant layers that provide an optimum mechanical index compatible with ultrasonics. Microbubble perfusion and/or nucleic acid delivery may be performed by a combination of imaging and ultrasound/microbubble targeted delivery to simultaneously perform low power two-dimensional imaging and high power microbubble destruction.Type: GrantFiled: April 15, 2011Date of Patent: December 19, 2017Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Flordeliza Villanueva, Andrew Carson, Charles F. McTiernan, Jianjun Wang
-
Publication number: 20160361443Abstract: The present invention is related to cardiovascular contrast agents. In particular, compositions and methods for ultrasound cardiovascular contrast agents useful for molecular imaging and/or diagnosis of cardiovascular diseases and disorders. For example, cardiovascular disorders comprising ischemia and/or myocardial injury may be imaged and diagnoses by the present invention.Type: ApplicationFiled: June 10, 2016Publication date: December 15, 2016Inventors: Flordeliza Villanueva, Bin Qin, Xucai Chen
-
Patent number: 8940277Abstract: This invention addresses the clinical problem of how to optimize biological cell based therapies, such as stem cell therapy. Currently, cell therapies administered by intravenous, intra-arterial, and/or direct tissue injection are limited by the lack of clinically available imaging methods to detect the in vivo fate of the administered cells. There are many efforts underway to develop imaging strategies for stem cells in vivo, including radionuclide and MRI-based approaches. However, these approaches are limited by potential safety issues (e.g. radioactive exposure of stem cells, toxicity of iron particles used for MRI) and difficulty in serial tracking due to complex instrumentation and/or the requirement for repetitive radiation exposure.Type: GrantFiled: November 5, 2009Date of Patent: January 27, 2015Assignee: University of Pittsburgh—of the Commonwealth System of Higher EducationInventors: Jianjun Wang, Flordeliza Villanueva, Xucai Chen, Andrew Fisher, William Richard Wagner
-
Patent number: 8460269Abstract: The disclosed technology describes compositions and methods useful for providing cell based therapy. For example, one embodiment of cell based therapy involves the regeneration of injured tissue and/or promoting wound healing. Certain embodiments provide improved therapeutic compositions using microbubbles by delivering biological progenitor cells to the injured tissues. The administration of the microbubbles is directed by acoustic radiation forces that interact with embodiments of microbubbles comprising an acoustically active gas. As such, a high efficiency of progenitor cell delivery to injured tissue is realized. One advantage of this technique over targeted delivery of pharmaceutical compounds, is that the delivered progenitors cells may be derived from the patient (i.e., personalized therapy), thereby avoiding side effects, allergic reactions, and overall problems associated with refractive drug responses.Type: GrantFiled: September 13, 2010Date of Patent: June 11, 2013Assignee: University of Pittsburgh—Of the Commonwealth System of Higher EducationInventors: Catalin Toma, Flordeliza Villanueva, William Richard Wagner, Joon S. Lee, Jianjun Wang, Xucai Chen, Andrew Fisher
-
Publication number: 20110208113Abstract: The disclosed technology describes compositions and methods useful for providing cell based therapy. For example, one embodiment of cell based therapy involves the regeneration of injured tissue and/or promoting wound healing. Certain embodiments provide improved therapeutic compositions using microbubbles by delivering biological progenitor cells to the injured tissues. The administration of the microbubbles is directed by acoustic radiation forces that interact with embodiments of microbubbles comprising an acoustically active gas. As such, a high efficiency of progenitor cell delivery to injured tissue is realized. One advantage of this technique over targeted delivery of pharmaceutical compounds, is that the delivered progenitors cells may be derived from the patient (i.e., personalized therapy), thereby avoiding side effects, allergic reactions, and overall problems associated with refractive drug responses.Type: ApplicationFiled: September 13, 2010Publication date: August 25, 2011Inventors: Catalin Toma, Flordeliza Villanueva, William Richard Wagner, Joon S. Lee, Jianjun Wang, Xucai Chen, Andrew Fisher
-
Publication number: 20100158815Abstract: This invention addresses the clinical problem of how to optimize biological cell based therapies, such as stem cell therapy. Currently, cell therapies administered by intravenous, intra-arterial, and/or direct tissue injection are limited by the lack of clinically available imaging methods to detect the in vivo fate of the administered cells. There are many efforts underway to develop imaging strategies for stem cells in vivo, including radionuclide and MRI-based approaches. However, these approaches are limited by potential safety issues (e.g. radioactive exposure of stem cells, toxicity of iron particles used for MRI) and difficulty in serial tracking due to complex instrumentation and/or the requirement for repetitive radiation exposure.Type: ApplicationFiled: November 5, 2009Publication date: June 24, 2010Inventors: Jianjun Wang, Flordeliza Villanueva, Xucai Chen, Andrew Fisher, William Richard Wagner